Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
Exclusive: Novo's Wegovy and Ozempic US advertising spend doubles rival Eli Lilly, data shows
06:07am, Wednesday, 28'th Jan 2026
Novo Nordisk spent nearly $500 million on U.S. advertising for its GLP-1 drugs Wegovy and Ozempic in the first nine months of 2025, more than double what Eli Lilly shelled out for its rival medicines,
Hussman Strategic Advisors Inc. Trims Stock Position in Novo Nordisk A/S $NVO
05:52am, Wednesday, 28'th Jan 2026
Hussman Strategic Advisors Inc. decreased its stake in Novo Nordisk A/S (NYSE: NVO) by 20.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commissi
1 Biotech Stock Set to Rebound in 2026
01:30am, Wednesday, 28'th Jan 2026
This weight-loss leader was drubbed last year. It's a popular pick as a 2026 rebound candidate.
Novo Nordisk (NVO) Stock Declines While Market Improves: Some Information for Investors
06:45pm, Tuesday, 27'th Jan 2026
Novo Nordisk (NVO) reached $62.89 at the closing of the latest trading day, reflecting a -1.7% change compared to its last close.
1 Pharmaceutical Stock Set to Rebound in 2026
12:40pm, Tuesday, 27'th Jan 2026
Novo Nordisk stock lost 40% of its value in 2025. The stock is already trading up 22% in 2026.
Novo Nordisk vs. Viking: Which Obesity Drug Stock is the Safer Bet?
10:45am, Tuesday, 27'th Jan 2026
NVO and VKTX face rising competition and setbacks as investors weigh scale, pipelines and execution risks in the crowded obesity drug race.
2 Pharmaceutical Stocks Set to Rebound in 2026
10:17am, Tuesday, 27'th Jan 2026
There might be massive upside ahead for these drugmakers.
Roche's Obesity Drug Helps Almost 87% People Lose At Least 10% Weight
06:21am, Tuesday, 27'th Jan 2026
Roche released Phase 2 trial results showing its weekly obesity drug CT-388 helped patients lose up to 22.5% body weight with strong tolerability and no weight loss plateau at 48 weeks.
Novo Nordisk: The Q4 Setup Favors Another Beat (Earnings Preview)
11:21am, Monday, 26'th Jan 2026
Novo Nordisk A/S's restructuring costs are front-loaded in Q3, with DKK 1 billion in savings accruing to Q4 earnings, setting up a potential beat on low expectations. The FDA-approved Wegovy oral pill
How Will Ozempic and Wegovy Sales Aid NVO's Upcoming Q4 Results?
10:16am, Monday, 26'th Jan 2026
Novo Nordisk's Q4 results hinge on Ozempic and Wegovy sales as demand growth slows amid guidance cuts due to intense rivalry and compounded drug headwinds.
Prediction: This Healthcare Stock Could Soar by 40% in 2026
09:00am, Monday, 26'th Jan 2026
Novo Nordisk had a rough stretch in 2025 that eventually led to it "firing" its CEO. The new Wegovy pill looks like a game-changer for the pharmaceutical giant.
Novo Nordisk Vs. Eli Lilly: The Tide May Be Turning For The Underdog
06:26am, Sunday, 25'th Jan 2026
Novo Nordisk was excessively punished by the market, trading at a significant discount to Eli Lilly despite robust fundamentals and global leadership in metabolic disease. NVO's global infrastructure,
Wealth Enhancement Advisory Services LLC Sells 17,117 Shares of Novo Nordisk A/S $NVO
05:22am, Saturday, 24'th Jan 2026
Wealth Enhancement Advisory Services LLC trimmed its holdings in Novo Nordisk A/S (NYSE: NVO) by 8.4% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange
Novo Nordisk: This Run Is Just Getting Started
03:41pm, Friday, 23'rd Jan 2026
Novo Nordisk A/S stock has jumped 30% since my last coverage. NVO's first-mover advantage in oral GLP-1 positions it well despite rising competition and pricing pressures in obesity and diabetes marke
Novo Nordisk Wegovy Pill Sees Strong Launch
12:58pm, Friday, 23'rd Jan 2026
Novo Nordisk (NVO, Financials) is off to a fast start with its new Wegovy weight loss pill, which saw more than 18,000 prescriptions written in its first week o
